2026年11月5日星期四
M
Hoàn Vũ Thông Giám
Tin nhanh toàn cầu
Japan's Yamato targets 'leaner' delivery service in push for profit: president— 日经 Nikkei AsiaToyota to bring Celica back to premier rally racing after 32-year break— 日经 Nikkei AsiaU.S. Steel grows to 40% of Nippon Steel profit as prices surge— 日经 Nikkei AsiaThe price of building Japanese stealth frigates in Australia— 日经 Nikkei AsiaMcDonald's wages war on KFC in Japan as consumers crave chicken— 日经 Nikkei AsiaJapan's Koito looks to keep lighting way with smart automotive lamps— 日经 Nikkei AsiaAnalysis: How a secret feud ignited Xi Jinping's governance drive— 日经 Nikkei AsiaJapan lender leads $600m credit line to help Malaysia's Petronas cut CO2— 日经 Nikkei AsiaJapan's Yamato targets 'leaner' delivery service in push for profit: president— 日经 Nikkei AsiaToyota to bring Celica back to premier rally racing after 32-year break— 日经 Nikkei AsiaU.S. Steel grows to 40% of Nippon Steel profit as prices surge— 日经 Nikkei AsiaThe price of building Japanese stealth frigates in Australia— 日经 Nikkei AsiaMcDonald's wages war on KFC in Japan as consumers crave chicken— 日经 Nikkei AsiaJapan's Koito looks to keep lighting way with smart automotive lamps— 日经 Nikkei AsiaAnalysis: How a secret feud ignited Xi Jinping's governance drive— 日经 Nikkei AsiaJapan lender leads $600m credit line to help Malaysia's Petronas cut CO2— 日经 Nikkei Asia

[Articles] Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial

Nguồn 柳叶刀 Lancet11 ngày trước
Tóm tắt nội dung

Mitapivat, an oral pyruvate kinase activator, with a novel mechanism that ameliorates haemolytic anaemia, has the potential to be an effective and convenient d…

Trang này chỉ cung cấp tiêu đề và chỉ mục tóm tắt, toàn bộ nội dung và bản quyền đều thuộc về bên phát hành gốc, vui lòng nhấp vào liên kết gốc để đọc.

Đi tới bài gốc
Kênh trực thuộc
Sức khỏe
Khu vực trực thuộc
Vương quốc Anh
Ngôn ngữ gốc
English
Số mục
health-94d31632

Comments 0 comments

No comments yet. Be the first.

[Articles] Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial · Hoàn Vũ Thông Giám